“36.6” did not rule out the sale of its distributor to a former top manager
By the end of 2020, the 36.6 company (pharmacy chains 36.6, Gorzdrav, etc.) at the general meeting of shareholders will consider a deal on the sale of its subsidiary LLC GDP – its distribution division, the message says. of the company that entered RBC.
The wholesale subsidiary may be sold to the former CEO of 36.6, Vladimir Nesterenko, who left this position at the end of October 2020, retaining his place on the company’s board of directors. The price of the possible deal was not disclosed.
According to the consulting company DSM Group, according to the results of the first half of 2020, GDP entered the top ten largest Russian distributors with a market share of 2.5%. The company was founded in 2015, specializing not only in the supply of drugs to the commercial sector, but also to the state. The distributor also supplies medical equipment to government agencies. In 2020, the company signed 1,297 contracts for a total amount of about 6 billion rubles, it follows from the SPARK database.
In the message, 36.6 explains that the deal will allow the company to focus on the development of pharmacy chains. Until 2019, the wholesale company provided up to 90% of all supplies to the 36.6 pharmacy chain, but in 2020, to improve business efficiency, the pharmacy chain switched to electronic auctions, purchasing goods from third-party distributors, including Katren JSC, PJSC “Protek” and FC “Pulse”. At the moment, the share of LLC “GDP” in supplies to “36.6” is only 34%.
“The Board of Directors believes that at the moment the merger of the retail and wholesale segments in the structure of one company is impractical and this may reduce the efficiency of work,” said Oksana Tarasova, Chairman of the Board of Directors of PJSC Pharmacy Chain 36.6. The company believes that the development of a distributor would require significant investments in the formation of a price offer and the creation of a regional logistics infrastructure; the company’s strategy does not imply such expenses. Tarasova added that the group’s pharmacy chains and GDP will continue their cooperation.
In 2019, the revenue of PJSC Pharmacy Chain 36.6 according to IFRS increased by 3.1% compared to 2018 and amounted to 46 billion rubles. The loss decreased 2.6 times – to 8.85 billion rubles.
Сообщение “36.6” did not rule out the sale of its distributor to a former top manager появились сначала на supercar.ru.